Clinical Trials Directory

Trials / Conditions / Hemophilia B With Inhibitor

Hemophilia B With Inhibitor

14 registered clinical trials studyying Hemophilia B With Inhibitor — 1 currently recruiting.

StatusTrialSponsorPhase
TerminatedThe Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC C
NCT06568302
ApcinteX LtdPhase 3
Active Not RecruitingEfficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors
NCT06312475
Suzhou Alphamab Co., Ltd.Phase 3
CompletedSS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
NCT06010953
Jiangsu Gensciences lnc.Phase 1 / Phase 2
TerminatedA Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors
NCT05789537
ApcinteX LtdPhase 2
CompletedA Phase I of SS109 in Hemophilia A or and B With Inhibitors
NCT05651061
Jiangsu Gensciences lnc.Phase 1
RecruitingSEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
NCT04647227
American Thrombosis and Hemostasis NetworkPhase 4
TerminatedStudy of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B
NCT04489537
Catalyst BiosciencesPhase 3
CompletedStudy on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibit
NCT04789954
AryoGen Pharmed Co.EARLY_Phase 1
UnknownStudy of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.
NCT04768699
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 1
CompletedStudy of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
NCT04072237
Catalyst BiosciencesPhase 1
CompletedATHN 7: Hemophilia Natural History Study
NCT03619863
American Thrombosis and Hemostasis Network—
CompletedATHN 8: Previously Untreated Patients (PUPs) Matter Study
NCT03818529
American Thrombosis and Hemostasis Network—
CompletedStudy of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and
NCT03407651
Catalyst BiosciencesPhase 2
CompletedProspective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
NCT03372993
AryoGen Pharmed Co.—